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Background: A clinical trial was designed to evaluate the effects of topical application of melatonin on the crevicu-
lar fluid levels of interleukins and prostaglandins and to evaluate changes in clinical parameters. 
Material and Methods: A consecutive sample of 90 patients were recruited from the Health Centre of Pinos Puente 
in Granada, Spain and divided into 3 groups:  30   patients with diabetes and periodontal disease, who were given 
melatonin; 30 patients with diabetes and periodontal disease, who were given a placebo, and 30 healthy individuals 
with no history of systemic disease or clinical signs of periodontal disease, who were also given a placebo. The 
30 patients with diabetes and periodontitis were treated with topical application of melatonin (1% orabase cream 
formula) for 20 days by. The rest of the patients with diabetes and periodontitis and healthy subjects were treated 
with a placebo of orabase cream. We measured the gingival index by exploring the percentage of standing teeth 
bleeding on probing. The periodontogram was performed with a Florida Probe. 
Results: In the diabetic patients who were given topical melatonin, there was a statistically significant decrease 
in the two clinical parameters. By contrast, in diabetic patients who were given the topical placebo, there was no 
statistically significant variation. 
Conclusions: In patients with diabetes and periodontal disease, treatment with topical melatonin was associated 
with a significant improvement in the gingival index and in pocket depth, and a statistically significant reduction in 
concentrations of interleukin-1β, interleukin-6 and prostaglandin E2 in gingival crevicular fluid.
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Introduction
Periodontal disease is an oral inflammatory process 
affecting the alveolar bone, the gums, and the periodon-
tal ligament (1). In advanced periodontitis, there is ex-
treme loss of gingival tissue and alveolar bone, with the 
possibility of tooth loss. The pathological mechanisms 
of periodontal disease are still not completely understo-
od. Microbial organisms in dental plaque are considered 
the primary pathogens of periodontal disease (2), howe-
ver the response of the host to the pathogens induces 
the production of inflammatory molecules, including 
cytokines and prostanoids, which are also involved in 
the initiation and progression of periodontal disease (3). 
Current knowledge of the pathogenesis of periodontitis 
suggests that it is a mixed infection in which the host 
response to bacterial biofilms is associated with high le-
vels of pro-inflammatory mediators (3). These mediators 
trigger a cascade of events which, in some individuals, 
culminates in the irreversible degradation of connective 
and bone tissues, and consequent periodontal attachment 
loss (4). Certain individuals seem to be more suscepti-
ble to periodontal disease and the variability in the host 
response seems to be a major cause of disease extension 
and increased severity (5). 
Many studies have shown that the biological activity of 
a variety of cytokines may be directly related to perio-
dontal destruction (6). There is mounting evidence that 
cyclooxygenase plays an important role in the produc-
tion of prostaglandin E2 (PGE2)  in periodontal disease 
(6). Selective cyclooxygenase inhibitors are as effecti-
ve as traditional non-steroidal anti-inflammatory drugs 
(NSAIDs) at inhibiting the progression of periodontal 
disease in animal models (7). In addition, interleukin-1β 
(IL-1β) and IL-6 are potent stimulators of prostaglan-
din production via cyclooxygenase-2 in human gingival 
fibroblasts (7). Il-6, IL-1β challenged human gingival 
fibroblasts induce a cyclooxygenase-2 expression via 
tyrosine kinase pathways (8). Numerous studies have 
shown elevated PGE2 levels in the gingiva and gingi-
val crevicular fluid of patients with periodontal diseases 
compared to periodontally healthy subjects (9). Pro-in-
flammatory mediators, including Il-6, IL-1β and PGE2 
are also associated with periodontal disease progression 
and alveolar bone resorption. Reductions in gingival 
crevicular fluid cytokines following initial periodontal 
therapy have also been reported (10).
Melatonin is an indoleamine secreted by the pineal gland 
in a circadian manner. It is now known that melatonin is 
produced in several organs and melatonin-forming en-
zymes are found in many tissues, including the retina, 
the ovaries, the gastrointestinal tract and immune sys-
tem cells, among others (11). Melatonin has revealed 
itself to be a pleiotropic multitasking molecule (12). It 
is a noteworthy free radical scavenger and also plays an 
immunomodulatory role (12). In addition to powerful 
antioxidant activity, melatonin has anti-inflammatory 
effects, preventing over-expression of pro-inflammatory 
mediators and inhibiting the effects of several pro-infla-
mmatory cytokines. The anti-inflammatory activity of 
melatonin has been consistently demonstrated in experi-
mental and clinical studies (13,14) and it may be able to 
protect the oral cavity against free radicals produced by 
inflammatory diseases (15). 
To further elucidate the anti-inflammatory activity of 
melatonin, we conducted clinical trials, aimed at de-
termining the effect of topical application of melatonin 
on gingival crevicular fluid levels of IL-6, IL-1β and 
PGE2 in patients with diabetes and periodontal disease 
and evaluating the changes in two clinical parameters, 
gingival index and pocket depth, and the interrelation 
between them. We also aimed to analyse the association 
between the severity of the periodontal disease in diabe-
tic patients and the increase in interleukin levels (IL-6, 
IL-1β and PGE2).  Our hypothesis was that local appli-
cation of melatonin improves the clinical parameters of 
the periodontal disease in diabetic patients with perio-
dontitis and that there is a positive correlation between 
the levels of IL-6, IL-1β and PGE2 and the severity of 
the periodontal disease in patients with diabetes.
Material and Methods
-Participants
We performed a consecutive selection of 90 patients 
from the Health Center in Pinos Puente (Granada, Spain) 
who met the inclusion/exlusion criteria over a period of 
4 months. We used the following inclusion criteria: a) 
diagnosed with diabetes mellitus, type 1 or type II; b) 
currently receiving pharmacological treatment for dia-
betes (oral antidiabetics or insulin); c) levels of HbA1C 
≥ 7%; and d) diagnosed with chronic periodontitis.
Patients had been previously diagnosed by their doctors 
according to the criteria established by the American 
Diabetes Association in 2010 (16): 1). Fasting plasma 
glucose ≥ 126 mg/dl (7.0 mmol/l), or 2). Glucose in 
plasma ≥ 200 mg/dl (11.1 mmol/l) at 2h during an oral 
glucose tolerance test or 3). Classic symptoms of hyper-
glycemia, or hyperglycemia crises, and the random plas-
ma glucose test ≥200 mg/dl (11.1mmol/l), or 4). HbA1C 
≥ 6.5%.
The clinical parameters of gingival index and pocket 
depth were used for the diagnosis of periodontitis. 
Exclusion criteria were as follows: a) suffering from 
another important chronic inflammatory disease; b) the 
use of bisphosphonates, oral contraceptives, treatment 
with NSAIDs or antibiotics in the previous 6 months; 
c) being a smoker; d) being edentulous; e) not having 
the target teeth used in the Probe, and f) having received 
topical treatment for oral diseases, such as mouth-rinses 
or gels within the last 6 months.
We also selected from companions a group of healthy 
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subjects with no evident oral or general pathologies of 
similar age and sex to those in the diabetic group, in or-
der to compare the behaviour of crevicular fluid levels 
of IL-1β, IL-6 and PGE2 between healthy subjects and 
diabetic patients with periodontal disease.
A total of 90 people took part in the study. These were 
divided into 3 groups:  Group 1 (DMPaMT): made up of 
30 patients with diabetes and periodontal disease who 
were administered topical melatonin; Group 2 (DMP-
Placebo): 30 patients with diabetes and periodontal di-
sease, who were given a placebo, and Group 3 (NoDM): 
30 healthy individuals with no history of systemic disea-
se or clinical signs of periodontal disease, who were also 
given a placebo. The study was approved by the Ethics 
Committee of the Faculty of Odontology of the Univer-
sity of Granada (Spain). The research objectives were 
explained to the patients and later the written informed 
consent was obtained from all individual participants in-
cluded in the study.
-Study Procedures
The study was performed in two phases. In phase 1, 
Group DMPaMT and DMPPlacebo were compared for 
the effects of topical application of melatonin or placebo, 
on gingival crevicular fluid levels of interleukin (IL)-1β, 
interleukin (IL)-6 and prostaglandin E2 (PGE2), and we 
assessed the changes in the clinical parameters (gingival 
index and pocket depth) in patients with diabetes and 
periodontal disease. In Phase 2 we compared the crevi-
cular fluid levels of IL-1β, IL-6 and PGE2 for members 
of the group of diabetics with periodontitis with those 
for members of the control group (Group DMPaMT and 
NoDM).
All participants in the study underwent an oral examina-
tion, including medical, dental, and caries assessments. 
The same highly experienced dentist performed all the 
examinations. To determine the gingival index we fo-
llow the established criteria Löe & Silness, 1963 (17), 
directly using the bleeding and depth levels obtained by 
the Florida Probe, considered suitable for evaluating the 
changes before and after the application of the melato-
nin and the placebo. We examined the same teeth spe-
cified in the Community Periodontal Index (CPI). The 
periodontogram was performed using the Florida Probe 
handpiece (computerized periodontal probing system), 
taking three probing points per vestibular and three per 
palate and lingual, recording the probe depth. The scores 
of the probing depth are expressed in mm.
We then treated 30 patients with diabetes and periodon-
titis with topical application of melatonin (1% orabase 
cream formula) in both the upper and lower dental ar-
ches on the surfaces of the attached gingiva for 20 days. 
The other patients with diabetes and periodontitis and 
the healthy subjects were treated with a placebo orabase 
cream. Melatonin and placebo were assigned to diabe-
tic periodontal patients at random by using blank clo-
sed envelopes. All the participants were instructed as 
to how to use the melatonin cream (or placebo), which 
they applied daily at night after routine oral hygiene; 
for each dental arch they were recommended to apply 
the amount that fits on a normal adult toothbrush. They 
used their toothbrushes as a reference for the amount of 
cream to use, spreading the gel across their gums. They 
were instructed not to brush this area, just to apply the 
cream.  In the morning they went through their normal 
dental hygiene routine. All the participants were given 
the same brand of toothpaste for use during the course 
of the study. Conventional periodontal treatment prior 
to or during the study was not allowed. All the baseline 
examinations were also performed just at the end of the 
treatment (20 days after). The examiner was blinded re-
garding the type of ointment (melatonin/placebo).
Melatonin was purchased in pure state from a company 
called Helsinn Advanced Synthesis SA. The melatonin 
in orobase gel for oral use at 1% was made by the Per-
petuo Socorro Company (from Granada, Spain), who 
also provided the gel with the placebo. The excipient for 
the placebo had identical characteristics to the gel with 
the melatonin. The quality certificate was provided by: 
Metapharmaceutical IND, SL. Jose Pla 163-Barcelona-
Spain.
-Measurements of Gingival Crevicular Fluid IL-1β, IL-6 
and PGE2
Periodontal pockets were sampled for gingival crevicu-
lar fluid, which was collected using paper strips (Perio-
paper strip, Harco Medical Electronic Devices, Tustin, 
CA, USA) prior to any periodontal probing. Samples 
were collected at two sites (mesio-buccal and disto-buc-
cal) from posterior teeth in each quadrant, excluding the 
third molars (9,18). The site was isolated and air-dried, 
and the fluid volume in each strip was measured by a ca-
librated electronic gingival fluid measuring device (18). 
IL-1β, IL-6 and PGE2 concentrations in the fluid were 
measured separately using ELISA (Cayman Chemical, 
Ann Arbor, MI, ISA). Results were expressed as ng/mL 
(IL-1β and PGE2) and as pg/ml (IL-6). 
-Statistical Analysis
The Shapiro-Wilk test was applied to verify the normal 
distribution of the continuous variables. Continuous va-
riables are expressed as the mean ± standard deviation 
(SD) if normally distributed. The Chi-squared test was 
used for the categorical variables. The paired Student’s 
t test was used for the comparison of the gingival index 
and the probing depth before and after topical appli-
cation of melatonin among diabetic patients with pe-
riodontal disease, and the ANOVA and Student’s t test 
for independent samples was used for comparing the 
crevicular fluid levels of IL-1β, IL-6 and PGE2 of the 
groups of diabetic patients and of healthy subjects. The 
relationship between the gingival index and the probing 
depth with crevicular fluid IL-1β, IL-6 and PGE2 was 
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assessed with the Pearson’s correlation coefficient. Sta-
tistical significance was set at p < 0.05. The Statistical 
analyses were performed using the R-Commander (ver-
sion 2.15.1 (2012-06-22). 
Results
The sample groups were shown to be homogenous in 
terms of age and sex, being mostly adults between 40-50 
yrs and slightly higher proportion of females (Table 1).
The sociodemographic and clinical characteristics of 
the patients by groups were: Group 1 (DMPaMT): 30 
patients with diabetes and periodontal disease (53.33% 
women) aged between 24 and 58 years (43.1 ± 12.4 yrs 
on average), 17 patients with type I diabetes (56.67%) 
and 13 with type II diabetes (43.33%); The Group 2 
(DMPPlacebo): 30 patients with diabetes and perio-
dontal disease (56.7% women) aged between 29 and 59 
years (45.46 ± 8.8 yrs on average), 12 patients with type 
I  diabetes (40%) and 18 with type II diabetes (60%). 
Group 3 (NoDM): 30 healthy individuals (60% women), 
aged between 31 and 68 years (47.0 ± 10.3 yrs on avera-
ge) without periodontal disease. The baseline Glycated 
haemoglobin levels (HbA1C %) in the diabetic groups 
were 8.4% ± 0.5 for the group that received topical me-
latonin and 7.7%±0.56 for the group that received the 
placebo. This difference was not significant (Table 1).
The comparison of gingival crevicular fluid levels of 
IL-1β, IL-6 and PGE2 between the different groups of 
diabetic patients with periodontal disease and healthy 
controls before topical treatment with melatonin or 
the placebo are shown in table 2. Patients with diabe-











Age (years), means ± SD  43.1±12.4 45.46±8.8 47.0±10.3 NS 
Sex Women (n, %) 16 (53.33%) 17 (56.67%) 18 (60%) NS 
 Men (n, %) 14 (46.67%) 13 (43.33%) 12 (40%) NS 
Type of Diabetes 
Mellitus 
Type 1 (n, %) 17 (56.67%) 12 (40%)  p<0.005 
 Type 2 (n, %) 13 (43.33%) 18 (60%)  p<0.005 
Glycated haemoglobin (%) 
(HbA1C), means ± SD 
8.39 ± 0.84 7.70±0.56  NS 
Table 1: Sociodemographic and clinical parameters of the three group of subjects.  
Abbreviations: diabetic patients with periodontitis who were given topical melatonin; DMPPlacebo, diabetic patients with 
periodontitis who were given a placebo; NoDM, healthy subjects without diabetes or periodontitis who were given a pla-
cebo; DMPaMT.
tes and periodontal disease from group DMPaMT and 
group DMPPlacebo had significantly higher mean le-
vels of IL-1β (127.73±99.50 and 122.47±95.2 ng/mL), 
IL-6 (0.57±0.56 and 0.56±0.007 pg/mL) and PGE2 
(265.42±101.6 and 263.45±98.7 ng/mL) than healthy 
subjects (IL-1β (95.35±59.26 ng/mL), IL-6 (0.38±0.005 
pg/mL) and PGE2 (205.71±118.09 ng/mL). However 
there were no significant differences between the two 
groups of diabetic patients (Table 2).
In the diabetic patients that received topical melatonin, 
there was a statistically significant decrease (before/af-
ter) in the gingival index (15.84 ± 10.26 vs 5.59 ± 4.08) 
and pocket depth (2.8 ± 1.9 vs 1.8 ± 1.2) as well as a 
significant decrease in gingival crevicular fluid levels 
of IL-1β (127.73 ± 99.50 vs 114.34 ± 74.88 ng/mL, P 
= 0.012), IL-6 (0.57 ± 0.07 vs 0.47 ± 0.07 pg/mL, P 
<0.001) and PGE2 (265.42 ± 101.60 vs 222.78 ± 87.88 
ng/mL, P < 0.001) (Table 3). However in the diabetic 
patients who received the topical placebo, there was no 
statistically significant change (before/after) in the gin-
gival index (14.51 ± 9.70 vs 14.13 ± 10.15) and the poc-
ket depth (2.7 ± 1.5 vs 2.6 ± 1.2), although there was a 
mild decrease in gingival crevicular fluid levels of IL-1β 
(122.47 ± 95.2 vs 120.93 ± 101.4 ng/mL), IL-6 (0.56 ± 
0.07 vs 0.54 ± 0.07 pg/mL) and PGE2 (263.45 ± 98.7 vs 
260.26 ± 99.1 ng/mL) as it is shown in Table 3.
There was also a direct and significant correlation bet-
ween the gingival crevicular fluid levels of IL-1β, IL-6 
and PGE2 and the periodontal parameters (gingival in-
dex and pocket depth) both at baseline and after the to-
pical melatonin treatment (Table 4). These correlation 





means ± SD 
DMPPlacebo 
means ± SD 
NoDM 
means ± SD 
Comparison 
IL-1  ng/mL* 127.73±99.50a 122.47±95.2 a 93.35±59.26 b p<0.001 
IL-6 pg/mL* 0.57±0.007 a 0.56±0.007 a 0.38±0.005 b p<0.001 
PGE2  ng/mL* 265.42±101.6 a 263.45±98.7 a 205.71±118.09 b p<0.001 
 
Table 2: Gingival crevicular fluid levels of IL-1β, IL-6 and PGE2 in patients from the three study groups before 
topical treatment.
*Statistically significant differences between the groups with distinct letters within a row in the table.
 
 
Topical Treatment for 20 days  
Before-after comparisons 


















      
Gingival index 15.84 ± 
10.26 
14.51 ± 9.70 5.59 ± 4.08 14.13 ± 10.15 < 0.001 NS 
Pocket depth (mm) 2.8 ± 1.9 2.7 ± 1.5 1.8 ± 1.2 2.6 ± 1.2 < 0.001 NS 
Crevicular fluid 
levels 
      
IL-1 , ng/mL 127.73 ± 
99.50 





IL-6, pg/mL 0.57 ± 0.07 0.56 ± 0.07 0.47 ± 0.07 0.54 ± 0.07 < 0.001 NS 
PGE2, ng/mL 265.42 ± 
101.60 
263.45 ± 98.7 222.78 ± 
87.88 
260.26 ± 99.1 < 0.001 NS 
 
 
Table 3: Comparison of gingival index, pocket depth and gingival crevicular fluid levels of IL-1β, IL-6 and PGE2 before and after topi-
cal application of melatonin or placebo in diabetic patients with periodontal disease (DMPaMT and DMPPlacebo).
Variables are expressed as means ± SD.
Gingival index Pocket depth 
Before  After Before  After 
IL-1 , ng/mL     
Before r = 0.899, P < 0.001 r = 0.657, P < 0.001 r = 0.945, P < 0.001 r = 0.880, P < 0.001 
After  r = 0.901, P < 0.001 r = 0.646, P < 0.001 r = 0.945, P < 0.001 r = 0.874, P < 0.001 
IL-6, pg/mL     
Before r = 0.569, P < 0.01 r = 0.484, P > 0.005 r = 0.609, P < 0.001 r = 0.417, P > 0.005 
After  r = 0.625, P < 0.001 r = 0.523, P < 0.005 r = 0.663, P < 0.001 r = 0.461, P < 0.01 
PGE2, ng/mL     
Before r = 0.909, P <0.001 r = 0.670, P < 0.001 r = 0.895, P < 0.001 r = 0.827, P < 0.001 




Table 4: Correlation between the periodontal parameters (gingival index and pocket depth) with the gingival crevicular fluid levels of IL-1β, 
IL-6 and PGE2 before and after treatment with melatonin in diabetic patients with periodontal disease. (DMPaMT).
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coefficients were higher for the IL-1β and PGE2 than for 
the IL-6, and were stronger for the baseline parameters 
than after treatment.
Discussion 
These results confirm the beneficial effects of the topi-
cal application of melatonin on clinical parameters for 
periodontal disease, such as the gingival index and the 
pocket depth. All comparisons before and after treatment 
with melatonin were statistically significant. Moreover, 
the anti-inflammatory action of melatonin was demons-
trated by a significant decrease in cytokines IL-1β, IL-6 
and PGE2 in gingival crevicular fluid of patients with 
diabetes and periodontal disease (19). However, to as-
sure that these treatment outcomes are because of the 
topical use rather than a systemic effect we should have 
analysed blood samples for quantifying melatonin levels 
before and after the topical treatment. Because since the 
melatonin was applied to the gingiva over 20 days on a 
daily basis, it may be plausible that part of the ointment 
was swallowed and worked systemically. 
Before treatment with melatonin, levels of IL-1β, IL-6 
and PGE2 in gingival crevicular fluid of patients with 
diabetes and periodontal disease were significantly hig-
her than in healthy control subjects without periodon-
titis. We should not forget that human adipose tissue is 
a potent source of inflammatory interleukins that could 
potentially lead us to a mistaken conclusion regarding a 
possible relationship between periodontal illness and the 
presence of interleukins (18), because in this study we 
did not measure the patient’s obesity (Body Mass Index. 
Our findings confirm that treatment with topical mela-
tonin of the periodontal disease among diabetic patients 
reduce significantly the presence of crevicular interleu-
kins. Furthermore previous studies have shown higher 
IL-1β and PGE2 crevicular fluid levels in subjects with 
either type 1 or type 2 diabetes than in subjects without 
diabetes, regardless of periodontal status (9,20). Probing 
depth and gingival index have been reported to be signi-
ficantly higher in poorly controlled diabetes compared to 
systemically healthy subjects, with positive associations 
between periodontal inflammation and levels of IL-1β 
in the gingiva and in gingival crevicular fluid (21,22). 
It has been suggested that hyperglycemia may induce 
inflammatory cytokine production (23). These studies 
suggest a possible dysregulation of the normal cytokine/
growth factor signalling axis in poorly controlled diabe-
tes that may contribute to periodontal breakdown/dimi-
nished repair (9). Overexpression of IL-6 and IL-1β in 
periodontally inflamed tissue has also been postulated as 
a mechanism by which type 2 diabetes enhances perio-
dontal destruction (24).
IL-1β is a potent bone-resorptive cytokine that also 
mediates soft-tissue destruction by stimulating prosta-
glandin production and inducing collagenase and other 
protease activity. The literature suggests that this subs-
tance may be an important mediator of attachment loss 
in human periodontitis, and indicates that IL-1β may be 
useful for locating sites of periodontal disease activity 
(20).  Studies on the determination of the IL-1 signaling 
cascades that lead to the production of various inflam-
matory mediators have shown that MAPK, AP-1 and 
NF-κB mediate the IL-1β-stimulated synthesis of IL-6, 
IL-8, PGE2 and MMP-1 in human periodontal ligament 
cells (25). Therefore, inhibition of activation of MAPK, 
AP-1 and/or NF-κB may lead to therapeutic effects in 
terms of the progression of periodontitis (25). In addi-
tion, periodontal ligament cells secrete IL-10, which can 
be suppressed by IL-1β and it has been hypothesized 
that periodontal ligament cells can function as accessory 
immunoinflammatory cells amplifying the inflammatory 
process in periodontitis, thereby contributing to perio-
dontal breakdown (26). Periodontal ligament cells acti-
vated by inflammatory factors such as IL-1β and PGE2 
may also directly stimulate osteoclastogenesis through 
RANKL (27).
For its part, IL-6 is an important pro-inflammatory cyto-
kine involved in the regulation of host response to tissue 
injury and infection. It is produced by a variety of cells, 
such as monocytes, fibroblasts, osteoblasts and vascular 
endothelial cells in response to inflammatory challenges 
(27). In our study, as in others (28), high levels of IL-6 
were found in patients with periodontal disease as com-
pared with healthy controls. 
Periodontal therapy has been shown to reduce levels of 
IL-1β in the gingival crevicular fluid. Removal of the 
bacterial plaque reduces the antigenic stimuli and con-
sequently could modulate the chemokines present in 
the gingival crevicular fluid (29). In general our results 
coincide with the findings of these authors, although in 
our study periodontal treatment was replaced by topi-
cal application of melatonin, whose positive effects in 
ameliorating periodontal disease had been demonstrated 
previously (15).
Conclusions
Treatment of patients with diabetes and periodontal di-
sease with topical melatonin was associated with a sig-
nificant improvement in the gingival index and in pocket 
depth, and a statistically significant reduction in concen-
trations of IL-1β, IL-6 and PGE2 in gingival crevicular 
fluid.
Patients with diabetes and periodontal disease had sig-
nificantly higher mean levels of IL-1β, IL-6 and PGE2 
than healthy subjects. 
There was a direct and strong correlation between clini-
cal periodontal parameters and the changes in crevicular 
fluid levels of IL-1β, IL-6 and PGE2 before and after 
topical melatonin treatment. 
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